BridgeBio's Acoramidis Nears FDA Approval, Challenges Pfizer and Faces New Rivals

In comparing BridgeBio's acoramidis and Pfizer's tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment, several key differences and potential advantages emerge. Acoramidis is poised to challenge tafamidis with its stronger stabilizing effects on the TTR protein, showcasing a stabilization rate of 96% compared to tafamidis' 50%[1]. Moreover, in the ATTRibute-CM phase 3 trial, acoramidis demonstrated a reduction in all-cause mortality and recurrent cardiovascular-related hospitalizations by significant margins compared to placebo, which could position it favorably as a first-line treatment option[2]. Nonetheless, acoramidis faces hurdles due to its twice-daily dosing requirement and the absence of conclusive cardiovascular mortality benefit data on its label, which may affect its market adoption despite potentially better efficacy results compared to tafamidis[1].